• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Minerals
    Tech
    Life Science
    Pharmaceutical Market
    Pharmaceutical News
    Pharmaceutical Stocks
    • Pharmaceutical Market
    • Pharmaceutical News
    • Pharmaceutical Stocks
    pharmaceutical-investing

    Cosmos Holdings Shares Q3 2017 Financial Results

    Bryan Mc Govern
    Nov. 28, 2017 09:16AM PST
    Pharmaceutical Investing

    Cosmos Holdings announced its financial results for the third quarter of 2017.

    Cosmos Holdings (OTCQB:COSMD) announced its financial results for the third quarter of 2017.
    As quoted in the press release:

    Highlights:

    • Quarter ended September 30, 2017, versus the quarter ended September 30, 2016, revenue improved 575% to $9.5 million from $1.4 million.
    • Revenue improved sequentially 56%, from $6.1 million in the 2017 second quarter to $9.5 million in the 2017 third quarter.
    • Gross profit increased 434% to $774,813 in the third quarter of 2017 from $144,950 in the third quarter of 2016.
    • Nine-month period ended September 30, 2017, versus the nine-month period ended September 30, 2016, revenue improved 464% to $19.7 million from $3.5 million.
    • Gross profit increased 415% to $1,618,603 in the nine months ended 2017 from $314,332 in the nine months ended 2016.
    • Cosmos expanded its sales network to another four countries; its current network consists of over 110 customers and vendors in 16 different countries.
    • Cosmos continues to diversify customer and vendor base, reducing client concentration risk and fueling the company’s future growth.
    • Cosmos’s clients include some of the largest European wholesalers.

    Click here to read the full press release.

    Source: www.marketwired.com

    pharmaceutical-investingfinancial-results
    The Conversation (0)

    Go Deeper

    AI Powered

    Cronos Group Reports 2024 First Quarter Results

    BioSyent Posts Q1 2017 Financials

    Latest News

    Outlook Reports world

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Pharmaceutical Investing Stocks

    InMed Pharmaceuticals

    InMed Pharmaceuticals (INM)
    INM

    Cardiol Therapeutics

    Cardiol Therapeutics (CRDL:CC)
    CRDL:CC
    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES